3 completed, 1 withdrawn. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Clostridium Difficile-associated Diarrhea: new trials by email Literature Review of Clostridium Difficile-associated Diarrhea trials Research Report on Clostridium Difficile-associated Diarrhea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) fidaxomicin - Clostridium Difficile-associated Diarrhea | Phase 2 | Completed | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2012-06-15 | 2018-09-18 |
| Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies Colostrum - Clostridium Difficile-Associated Diarrhea | Phase 2 / Phase 3 | Withdrawn | Hadassah Medical Organization | 2011-09-01 | 2012-08-28 | |
| Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection BIO-K+ CL-1285®, Placebo - Antibiotic-Associated Diarrhea, Clostridium Difficile-Associated Diarrhea | Phase 3 | Completed | Bio-K Plus International Inc. | 255 | 2008-12-01 | 2012-03-13 |
| A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea GT160-246 - Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis | Phase 2 | Completed | Genzyme, a Sanofi Company | 300 | 2002-02-01 | 2015-03-05 |
Diarrhea (1) · Dysentery (1) · Enterocolitis, Pseudomembranous (1)
Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Clostridium Infections (1) · Digestive System Diseases (1) · Enterocolitis (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Intestinal Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Signs and Symptoms, Digestive (1)
Fidaxomicin (1) · OPT 80 (1) · styrenesulfonic acid polymer (1)
Bio-K Plus International Inc. (1) · Genzyme, a Sanofi Company (1) · Hadassah Medical Organization (1) · Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
Canada (1) · Israel (1) · Puerto Rico (1) · United Kingdom (1) · United States (1)
Gao XingWang, MD (1)